Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep-Oct;39(5):1548-1554.
doi: 10.12669/pjms.39.5.6300.

Pakistan National Guidelines for Pediatric High-Grade Gliomas

Farrah Bashir  1 , Bilal Mazhar Qureshi  2 , Khurram Minhas  3 , Uri Tabori  4 , Eric Bouffet  5 , Cynthia Hawkins  6 , Ather Enam  7 , Naureen Mushtaq  8
Affiliations

Pakistan National Guidelines for Pediatric High-Grade Gliomas

Farrah Bashir et al. Pak J Med Sci. 2023 Sep-Oct.

Abstract

Pediatric high-grade glioma (pHGG) is highly malignant central nervous system tumor and constitute 10% of the pediatric gliomas. Effective treatment needs a functioning multi-disciplinary team including pediatric neuro oncologist, neurosurgeon, neuroradiologist, neuropathologist and radiation oncologist. Despite surgical resection, radiotherapy and chemotherapy, most HGG will recur resulting in early death. A significant proportion of HGG occurs in context of cancer predisposition syndromes like Constitutional Mismatch Repair Deficiency (CMMRD) also known as Biallelic Mismatch Repair Deficiency (bMMRD) characterized by high mutational burden. The incidence of HGG with CMMRD is one per million patients. bMMRD is caused by homozygous germline mutations in one of the four Mis Match Repair (MMR) genes (PMS2, MLH1, MSH2, and MSH6). The use of TMZ is now avoided in CMMRD related HGG due to its limited response and known ability to increase the accumulation of somatic mutations in these patients, increasing the risk of secondary tumors. HGG should be managed under the care of multidisciplinary team to receive optimum treatment. This is particularly important for low middle-income countries (LMIC) with limited resources like Pakistan.

Keywords: Central Nervous System Tumor; Germline Mutation; Guidelines; Mismatch Repair Genes PMS2; Temozolomide.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None.

Figures

Fig.1
Fig.1
Flow chart One.
Fig.2
Fig.2
Flow chart Two.
See this image and copyright information in PMC

References

    1. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas:Result from the CCG-945 Cohort. J Clin Oncol. 2006;24(21):3431–3437. doi: 10.1200/JCO.2006.05.7265. - PubMed
    1. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et al. Temozolomide in the treatment of high-grade gliomas in children:a report from the Children's Oncology Group. J Clin Oncol. 2011;13(3):317–323. doi: 10.1093/neuonc/noq191. - PMC - PubMed
    1. Finley JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisolone with eight-in-1-day regime. Childrens Cancer Group. J Clin Oncol. 1995;13(1):112–123. doi: 10.1200/JCO.1995.13.1.112. - PubMed
    1. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - PubMed
    1. Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children:results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165–177. doi: 10.1007/BF00165101. - PubMed

LinkOut - more resources